The Monoclonal anti-SRA1 antibody has been validated for WB, ELISA and IHC. It is suitable to detect SRA1 in samples from Human. There are 3+ publications available.
SRA1
Reactivity: Human
WB, IP
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Western Blot: 1: 500- 1: 2,000 IHC(P): 1: 500- 1: 2,000 IHC(F): 1: 500- 1: 2,000 ELISA: Propose dilution 1: 10,000 Determining optimal working dilutions by titration test.
Restrictions
For Research Use only
Format
Liquid
Storage
-20 °C
Chooniedass-Kothari, Hamedani, Troup, Hubé, Leygue: "The steroid receptor RNA activator protein is expressed in breast tumor tissues." in: International journal of cancer. Journal international du cancer, Vol. 118, Issue 4, pp. 1054-9, (2006) (PubMed).
Chooniedass-Kothari, Emberley, Hamedani, Troup, Wang, Czosnek, Hube, Mutawe, Watson, Leygue: "The steroid receptor RNA activator is the first functional RNA encoding a protein." in: FEBS letters, Vol. 566, Issue 1-3, pp. 43-7, (2004) (PubMed).
Lanz, Chua, Barron, Söder, DeMayo, OMalley: "Steroid receptor RNA activator stimulates proliferation as well as apoptosis in vivo." in: Molecular and cellular biology, Vol. 23, Issue 20, pp. 7163-76, (2003) (PubMed).
Target
SRA1
(Steroid Receptor RNA Activator 1 (SRA1))
Alternative Name
SRA
Background
Steroid receptor RNA activator 1 (SRA), with 237-amino acid protein (about 27kDa), belongs to the growing family of functional non-coding RNAs. SRA was originally described as the first functional noncoding RNA able to specifically coactivate the activity of steroid receptors. Specifically, SRA exists as both an RNA transcript that forms a complex with steroid receptor coactivator-1 and as a stably expressed protein. Its expression is strongly up-regulated in many human tumors of the breast, uterus, and ovary, suggesting a potential role in pathogenesis. Although coactivation of steroid-dependent transcription by SRA is accompanied by a proliferative response, overexpression is not in itself sufficient to induce turmorigenesis.